๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Refractory Non-Hodgkin Lymphoma
Clinical trial register · United States · industry-sponsored

Refractory Non-Hodgkin Lymphoma Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 4 Florida 3 Georgia 3 Texas 2 Colorado 2
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Lyell Immunopharma, Inc.2 SIRPant Immunotherapeutics, Inc.1 FBD Biologics Limited1 Indapta Therapeutics, INC.1
State
California4 Florida3 Georgia3 Texas2 Colorado2
All 20 states
Target enrolment
to
5 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Recruiting
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05967416Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
SIRPant Immunotherapeutics, Inc.
Phase 1
24
California, New Jersey, Texas
2024-01-17
Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
Recruiting
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPฮฑ-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
FBD Biologics Limited
Phase 1
80
Florida, North Carolina, South Carolina, Texas
2023-10-02
Recruiting
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2
270
California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky, Louisiana
2023-05-09
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/refractory-non-hodgkin-lymphoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.